Kingsview Wealth Management LLC Purchases 15,789 Shares of Becton, Dickinson and Company $BDX

Kingsview Wealth Management LLC grew its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 448.9% during the 3rd quarter, Holdings Channel.com reports. The firm owned 19,306 shares of the medical instruments supplier’s stock after acquiring an additional 15,789 shares during the period. Kingsview Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $3,613,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Activest Wealth Management grew its position in Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 97 shares during the last quarter. SOA Wealth Advisors LLC. boosted its stake in shares of Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 95 shares in the last quarter. Bell Investment Advisors Inc grew its holdings in shares of Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares during the last quarter. Accredited Wealth Management LLC raised its position in Becton, Dickinson and Company by 77.8% in the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 70 shares during the period. Finally, Cornerstone Planning Group LLC lifted its stake in Becton, Dickinson and Company by 463.3% in the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 139 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the transaction, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 3,416 shares of company stock valued at $674,693 over the last 90 days. 0.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Morgan Stanley lifted their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. JPMorgan Chase & Co. decreased their price target on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 10th. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Finally, Jefferies Financial Group lowered their price target on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Five investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $195.46.

Becton, Dickinson and Company Price Performance

BDX opened at $171.80 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.58 and a current ratio of 1.05. The stock has a market capitalization of $48.92 billion, a PE ratio of 28.03, a price-to-earnings-growth ratio of 12.63 and a beta of 0.24. The stock’s 50 day moving average price is $194.37 and its 200-day moving average price is $191.61. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter in the previous year, the business posted $3.43 earnings per share. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share buyback program on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to buy up to 0% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is presently 68.52%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.